Author

Remo Panaccione

BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE NOT IN CLINICAL RESPONSE AT WEEK 12: RESULTS FROM THE GALAXI 1 STUDY
EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE NOT IN CLINICAL RESPONSE AT WEEK 12: RESULTS FROM THE GALAXI 1 STUDY

Remo Panaccione  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY

RISANKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE WHO FAILED 1 VS >1 PRIOR BIOLOGIC TREATMENT: RESULTS FROM THE MOTIVATE STUDY
RISANKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE WHO FAILED 1 VS >1 PRIOR BIOLOGIC TREATMENT: RESULTS FROM THE MOTIVATE STUDY

Remo Panaccione

EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)

Remo Panaccione  et al.

UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY
UPADACITINIB 30 MG TREATMENT RESTORES CLINICAL RESPONSE AFTER LOSS OF RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 U-ENDURE STUDY

Remo Panaccione  et al.

EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Remo Panaccione  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY

Remo Panaccione  et al.

THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB

Remo Panaccione  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY
MAINTENANCE OF CLINICAL, ENDOSCOPIC, AND BIOMARKER IMPROVEMENTS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF THE PHASE 3 U-ENDURE STUDY

Remo Panaccione  et al.

EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY

EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY

Remo Panaccione  et al.

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Remo Panaccione  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

Remo Panaccione  et al.

LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Remo Panaccione  et al.

EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

Remo Panaccione  et al.

ACHIEVEMENT OF LONG-TERM TREATMENT GOALS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF INDUCTION AND MAINTENANCE PHASE 3 TRIALS
ACHIEVEMENT OF LONG-TERM TREATMENT GOALS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF INDUCTION AND MAINTENANCE PHASE 3 TRIALS

Remo Panaccione  et al.

Item 1 - 20 / 71
1
2 3 4